Truvestments Capital’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-22
| Closed | -$75 | – | 1133 |
|
|
2025
Q2 | $75 | Hold |
22
| – | – | ﹤0.01% | 935 |
|
|
2025
Q1 | $62 | Hold |
22
| – | – | ﹤0.01% | 1008 |
|
|
2024
Q4 | $61 | Hold |
22
| – | – | ﹤0.01% | 997 |
|
|
2024
Q3 | $83 | Buy |
+22
| New | +$112 | ﹤0.01% | 912 |
|
|
2024
Q2 | – | Sell |
-22
| Closed | -$193 | – | 711 |
|
|
2024
Q1 | $193 | Hold |
22
| – | – | ﹤0.01% | 703 |
|
|
2023
Q4 | $164 | Hold |
22
| – | – | ﹤0.01% | 772 |
|
|
2023
Q3 | $220 | Hold |
22
| – | – | ﹤0.01% | 662 |
|
|
2023
Q2 | $227 | Hold |
22
| – | – | ﹤0.01% | 671 |
|
|
2023
Q1 | $231 | Hold |
22
| – | – | ﹤0.01% | 651 |
|
|
2022
Q4 | $280 | Buy |
+22
| New | +$326 | ﹤0.01% | 888 |
|
|
2022
Q3 | – | Sell |
-29
| Closed | -$1K | – | 661 |
|
|
2022
Q2 | $1K | Buy |
+29
| New | +$726 | ﹤0.01% | 632 |
|
|
2022
Q1 | – | Sell |
-29
| Closed | -$1K | – | 573 |
|
|
2021
Q4 | $1K | Hold |
29
| – | – | ﹤0.01% | 592 |
|
|
2021
Q3 | $2K | Hold |
29
| – | – | ﹤0.01% | 558 |
|
|
2021
Q2 | $3K | Hold |
29
| – | – | ﹤0.01% | 527 |
|
|
2021
Q1 | $3K | Buy |
29
+7
| +32% | +$776 | ﹤0.01% | 589 |
|
|
2020
Q4 | $0 | Buy |
+22
| New | +$814 | ﹤0.01% | 618 |
|
|
2019
Q4 | – | Sell |
-38
| Closed | -$4K | – | 621 |
|
|
2019
Q3 | $4K | Sell |
38
-4
| -10% | -$866 | ﹤0.01% | 613 |
|
|
2019
Q2 | $12K | Hold |
42
| – | – | 0.01% | 510 |
|
|
2019
Q1 | $20K | Buy |
+42
| New | +$16.3K | 0.02% | 400 |
|
|
2018
Q3 | $8K | Buy |
+44
| New | +$8.07K | ﹤0.01% | 688 |
|
Other funds holding CSCI
Truvestments Capital's CSCI Position: Q3 2025 in Review
Truvestments Capital sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2025, closing a stake of 22 shares — an estimated $75 sold.
Truvestments Capital first reported a position in CSCI in Q3 2018 and held it in 20 quarters. The position peaked at $20K in Q1 2019. 2 funds tracked by Wall St. Rank hold CSCI as of Q3 2025.
- Truvestments Capital reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
- Truvestments Capital sold 22 COSCIENS Biopharma Inc. Common Stock shares in Q3 2025, an estimated $75.
- Truvestments Capital first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2018 and held it in 20 quarters.
- Truvestments Capital's COSCIENS Biopharma Inc. Common Stock position peaked at $20K in Q1 2019.
- 2 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2025.
Based on Truvestments Capital's 13F filing for Q3 2025, filed 14 Nov 2025.